Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Current and Emerging Utility of Liquid Biopsy in Cancers. More than Surrogate Biomarkers"
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: 30 April 2023 | Viewed by 7783
Special Issue Editors
Interests: liquid biopsy and tumor cells biomarkers in genitourinary tumors
Special Issue Information
Liquid biopsy has emerged as a reliable tool for tumor surveillance, studying disseminated tumor cells in bone marrow and circulating tumor cells in peripheral blood and providing crucial insights into cancer biology and the metastatic process. More recently, the development of the detection and characterization of circulating tumor DNA (ctDNA) and other molecules either free or as extracellular vessels has finally enabled the arrival of liquid biopsy assays into clinical practice; however, little is known about the circulating tumor microenvironment either at the cellular or biomarker level and its potential implementation to help define the best molecularly targeted therapies for cancer. In this context, this Special Issue will focus on the next frontier for the clinical application of liquid biopsy in cancer treatment, cancer screening, diagnosis, follow-up, and the best personalized therapies as potential future applications. We would like to develop a compendium issue centered in technology, methodologies, and logistics for the eventual integration of liquid biopsy into the clinical workflow.
We are pleased to invite you to participate in this Special Issue that will focus on the state of the art and the latest findings on circulating tumor biomarkers, circulating tumor cells (CTCs), tumor hybrid cells (THCs), as well as ctDNA and ctRNA (coding and noncoding) and protein analysis, and clinical evidence regarding the implementation of liquid biopsy in clinical practice.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Implication of liquid biopsy in cancer diagnosis, prognosis, and clinical management;
- More than circulating tumor cells in blood sample characterization;
- DNAs, RNAs, and proteins as cancer biomarkers in biofluids;
- Liquid biopsy approximations in immunotherapy response prediction.
We look forward to receiving your contributions.
Dr. Marta Dueñas
Dr. Rodrigo Toledo
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- liquid biopsy
- cytokine profiling
- tumor biomarkers